Pepfar authorisation delay could cause “substantial increase in new HIV infections”, leading health experts warn
Leading medical scientists have expressed “deep concern” that the US Congress has failed to reauthorise the US President’s Emergency Program for Aids Relief, set to expire on 30 September.
For the past 20 years, Pepfar has funded prevention and treatment programmes in 55 countries, changing a HIV diagnosis from a death sentence into a manageable condition for millions of people, the scientists wrote in the New England Journal of Medicine on 9 September.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.